Long-Term Efficacy Of Dupilumab In Adults With Moderate-to-Severe Atopic Dermatitis: Results From A 5-Year Open-Label Extension Trial

Patients with moderate-to-severe atopic dermatitis (AD) often respond inadequately to topical therapy. We assessed the long-term efficacy of dupilumab for up to 5 years in adults with moderate-to-severe AD.